Holz Frank G

Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population.

In addition to previously described determinants such as age and refraction, we found that systemic vascular and neurovascular diseases were associated with reduced pRNFLT.

Clinical outcomes of the PAUL® glaucoma implant: One-year results.

PGI surgery is an effective procedure for reducing IOP and pressure-lowering therapy. An intraluminal prolene stent impedes hypotony in the early postoperative phase and enables further IOP lowering without additional interventions during the postoperative course.

Determinants of Macular Layers and Optic Disc Characteristics on SD-OCT: The Rhineland Study.

We provide large-scale normative data from a Caucasian general population for various SD-OCT measures.

Two-Year Clinical Outcomes of the PAUL Glaucoma Implant in White Patients With Refractory Glaucoma.

PGI surgery is an effective procedure for reducing IOP and pressure-lowering therapy.

Five-Year Clinical Outcomes of Inferior Quadrant Trabectome Surgery for Open Angle Glaucoma.

Trabectome surgery is a safe and relatively effective procedure for lowering IOP, but most patients still need IOP-lowering agents, and a considerable proportion may need additional glaucoma surgery within a relatively short time.

Sonographic bleb visualisation after PAUL glaucoma implant surgery.

Sonography is a suitable modality to evaluate bleb characteristics after PGI implantation.

Anterior segment OCT for imaging PAULglaucoma implant patch grafts: a useful method for follow-up and risk management.

Pericardial patch grafts tend to thin over time which can be assessed by AS-OCT, the latter proving to be a useful method to follow-up patients who undergo patch graft implantation during PGI surgery.

Clinical outcomes of the PAUL glaucoma implant in primary open-angle and pseudoexfoliative glaucoma eyes after failed glaucoma surgeries.

In conclusion, the PGI demonstrated significant IOP reduction and decreased need for medication in both POAG and PEXG patients, with no major differences between the two groups at 12 months.

Clinical outcomes of the PAUL® Glaucoma implant for refractory glaucoma: three-year results.

PGI surgery effectively reduces IOP and medication burden in refractory glaucoma, with sustained efficacy over three years. The intraluminal Prolene stent enables further non-invasive IOP reduction postoperatively.

Clinical outcomes of the EyeWatch system: three-year results.

Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention.

Comparing the use of Tutopatch® pericardium with Tutoplast® fascia lata in the context of PAUL® glaucoma implant surgery: an anterior segment OCT study.

This study shows that AS-OCT is a useful method for comparing different patch materials after PGI surgery.

Clinical outcomes of the PAUL Glaucoma implant for neovascular glaucoma.

The PGI demonstrates significant IOP reduction in NVG, with sustained success at higher IOP thresholds. However, maintaining very low IOP levels remains challenging.

Clinical Outcomes of Intraluminal Stent Removal After PAUL Glaucoma Implant Surgery.

Removal of the prolene stent following PGI surgery effectively lowers IOP in the short term, with a moderate increase in IOP and need for pressure-lowering therapy over time.

Ocular drug delivery systems: glaucoma patient perceptions from a German university hospital eye clinic.

ODD for the treatment of glaucoma were broadly deemed acceptable by patients in this study.